StreetInsider.com News Articles

BioNxt closes $2M private placement at $0.33 per unit

Tue, 23 Jun 2026 17:20:09 -0400

BioNxt Solutions Inc. (CSNX: BNXT)(OTCQB: BNXTF)(FSE: BXT) has closed a non-brokered private placement under the Listed Issuer Financing Exemption, issuing 6,060,606 units at $0.33 each for gross proceeds of approximately $2 million.

Each unit consists of one common share and one share purchase warrant. Each warrant allows the holder to purchase one additional share at $0.50 for 24 months from the closing date. The securities issued are not subject to a hold period under applicable Canadian securities laws.

The company paid $120,000 in cash finder's fees and issued 363,636 non-transferable finder's warrants to an arm's length finder, also exercisable at $0.50 per

BioNxt Announces Closing of Non-brokered Private Placement of Units Pursuant to the Listed Issuer Exemption

Tue, 23 Jun 2026 17:20:00 -0400

Not for distribution to U.S. newswire services or for dissemination in the United States.

VANCOUVER, BC / ACCESS Newswire / June 23, 2026 / BioNxt Solutions Inc. (CSNX:BNXT)(OTCQB:BNXTF)(FSE:BXT) (the "Company" or "BioNxt") is pleased to announce that it has closed its previously announced non-brokered private placement (the "LIFEOffering") of units of the Company ("Units") pursuant to the Listed Issuer Financing exemption available under Part 5A of National Instrument 45-106 - Prospectus Exemptions. Pursuant to the LIFE Offering, the Company issued an aggregate of 6,060,606 Units at a price of $0.33 per Unit

BioNxt Announces Closing of Non-brokered Private Placement of Units Pursuant to the Listed Issuer Exemption

Tue, 23 Jun 2026 17:20:00 -0400

Not for distribution to U.S. newswire services or for dissemination in the United States.

BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF

Mon, 15 Jun 2026 03:45:00 -0400

VANCOUVER, BC / ACCESS Newswire / June 15, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that it has commenced work with a Business Development & Licensing ("BD&L") specialist advisor to support the commercialization and partnering strategy for BNT23001, the Company's patented proprietary sublingual Cladribine orally dissolvable film ("ODF") formulation for the treatment of multiple sclerosis ("MS").

BNT23001 is designed as a differentiated alternative to conventional tablet-based Cladribine therapy, including Mavenclad^®, by offering a thin, dissolvable film placed

BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF

Mon, 15 Jun 2026 03:45:00 -0400

BNT23001 is designed as a differentiated alternative to conventional tablet-based Cladribine therapy, including Mavenclad^®, by offering a thin, dissolvable film placed

BioNxt Solutions Inc. Announces Extension of Convertible Debentures and Issuance of Warrants

Wed, 10 Jun 2026 18:30:00 -0400

VANCOUVER, BC / ACCESS Newswire / June 10, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:4XT) announces that it has amended the terms of previously issued unsecured convertible debentures in the principal amounts of $425,000, $285,000, $1,400,000, $865,000, $1,600,000, and $900,000, bearing interest at a rate of 8% per annum and maturing on November 12, 2026, November 29, 2026, December 19, 2026, January 14, 2027, February 28, 2027, and March 14, 2027, respectively (the "Debentures").

The Company has amended the Debenturesto extend the maturity dates of the Debentures by one year

BioNxt Solutions Inc. Announces Extension of Convertible Debentures and Issuance of Warrants

Wed, 10 Jun 2026 18:30:00 -0400

The Company has amended the Debenturesto extend the maturity dates of the Debentures by one year

BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development

Tue, 19 May 2026 03:05:00 -0400

VANCOUVER, BC / ACCESS Newswire / May 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that its Semaglutide oral dissolvable film ("ODF") program has entered the active pharmaceutical development phase in collaboration with German drug development partner Gen-Plus GmbH.

The advancement represents a significant strategic milestone for BioNxt as the Company applies its expertise in sublingual thin-film drug delivery systems beyond neurological and autoimmune diseases into the rapidly growing global GLP-1 therapeutics market.

Applying BioNxt's Thin-Film Expertise to

BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development

Tue, 19 May 2026 03:05:00 -0400

VANCOUVER, BC / ACCESS Newswire / May 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that its Semaglutide oral dissolvable film ("ODF") program has entered the active pharmaceutical development phase in collaboration with German drug development partner Gen-Plus GmbH.
The advancement represents a significant strategic milestone for BioNxt as the Company applies its expertise in sublingual thin-film drug delivery systems beyond neurological and autoimmune diseases into the rapidly growing global GLP-1 therapeutics market.
Applying BioNxt's Thin-Film Expertise to

BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum

Tue, 28 Apr 2026 03:05:00 -0400

VANCOUVER, BC / ACCESS Newswire / April 28, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that it is evaluating opportunities to apply its proprietary drug delivery technologies to the emerging field of psychedelic therapeutics in response to accelerating regulatory, clinical, and policy momentum globally.
Recent developments in the United States, including policy initiatives aimed at expanding and accelerating research pathways for investigational therapies addressing serious mental health conditions such as post-traumatic stress disorder, depression, and addiction, signal

BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum

Tue, 28 Apr 2026 03:05:00 -0400

VANCOUVER, BC / ACCESS Newswire / April 28, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that it is evaluating opportunities to apply its proprietary drug delivery technologies to the emerging field of psychedelic therapeutics in response to accelerating regulatory, clinical, and policy momentum globally.
Recent developments in the United States, including policy initiatives aimed at expanding and accelerating research pathways for investigational therapies addressing serious mental health conditions such as post-traumatic stress disorder, depression, and addiction, signal

BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)

Tue, 14 Apr 2026 03:05:00 -0400

VANCOUVER, BC / ACCESS Newswire / April 14, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the successful completion of Good Manufacturing Practice (GMP) manufacturing of its clinical-grade sublingual Cladribine oral thin film (ODF) at its GMP manufacturing partner (CDMO) based in Munich, Germany.
The completed GMP production campaign represents a significant operational milestone for BioNxt's lead development program, BNT23001, a proprietary sublingual Cladribine formulation designed for the treatment of relapsing forms of multiple sclerosis (MS) and other

BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)

Tue, 14 Apr 2026 03:05:00 -0400

VANCOUVER, BC / ACCESS Newswire / April 14, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the successful completion of Good Manufacturing Practice (GMP) manufacturing of its clinical-grade sublingual Cladribine oral thin film (ODF) at its GMP manufacturing partner (CDMO) based in Munich, Germany.
The completed GMP production campaign represents a significant operational milestone for BioNxt's lead development program, BNT23001, a proprietary sublingual Cladribine formulation designed for the treatment of relapsing forms of multiple sclerosis (MS) and other

BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries

Tue, 07 Apr 2026 03:05:00 -0400

VANCOUVER, BC / ACCESS Newswire / April 7, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the official registration of unitary effect for European Patent No. 4539857 covering the Company's proprietary sublingual cladribine oral thin film (ODF) platform.
The European Patent Office registered the patent's unitary effect on March 31, 2026, with effect from March 11, 2026. The Unitary Patent provides centralized protection across 18 participating European countries, including major pharmaceutical markets such as Germany, France, Italy, the

BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries

Tue, 07 Apr 2026 03:05:00 -0400

VANCOUVER, BC / ACCESS Newswire / April 7, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the official registration of unitary effect for European Patent No. 4539857 covering the Company's proprietary sublingual cladribine oral thin film (ODF) platform.
The European Patent Office registered the patent's unitary effect on March 31, 2026, with effect from March 11, 2026. The Unitary Patent provides centralized protection across 18 participating European countries, including major pharmaceutical markets such as Germany, France, Italy, the

BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy

Mon, 30 Mar 2026 03:05:00 -0400

VANCOUVER, BC / ACCESS Newswire / March 30, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to provide an update on its semaglutide oral thin-film (ODF) program and its broader strategy to develop a scalable platform for GLP-1 receptor agonists and peptide-based therapeutics.
Semaglutide as Lead Candidate for GLP-1 Platform Validation
BioNxt is currently in early-stage development of its semaglutide ODF program, with initial formulation work underway, including preliminary feasibility and exploratory proof-of-concept evaluations. Semaglutide, a leading GLP-1 receptor agonist widely

BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy

Mon, 30 Mar 2026 03:05:00 -0400

VANCOUVER, BC / ACCESS Newswire / March 30, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to provide an update on its semaglutide oral thin-film (ODF) program and its broader strategy to develop a scalable platform for GLP-1 receptor agonists and peptide-based therapeutics.
Semaglutide as Lead Candidate for GLP-1 Platform Validation
BioNxt is currently in early-stage development of its semaglutide ODF program, with initial formulation work underway, including preliminary feasibility and exploratory proof-of-concept evaluations. Semaglutide, a leading GLP-1 receptor agonist widely

BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform

Tue, 24 Mar 2026 05:10:00 -0400

VANCOUVER, BC / ACCESS Newswire / March 24, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce a major advancement in its commercialization strategy, supported by a rapidly expanding global patent portfolio for its proprietary sublingual drug delivery platform.
BioNxt has established a broad and defensible intellectual property position across key global markets, forming the foundation for the commercialization of its lead product, BNT23001, a sublingual cladribine ODF, a thin, fast-dissolving film for oral drug delivery, targeting multiple sclerosis

BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform

Tue, 24 Mar 2026 05:10:00 -0400

VANCOUVER, BC / ACCESS Newswire / March 24, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce a major advancement in its commercialization strategy, supported by a rapidly expanding global patent portfolio for its proprietary sublingual drug delivery platform.
BioNxt has established a broad and defensible intellectual property position across key global markets, forming the foundation for the commercialization of its lead product, BNT23001, a sublingual cladribine ODF, a thin, fast-dissolving film for oral drug delivery, targeting multiple sclerosis

BioNxt signs commercialization agreement for cladribine drug in Eurasia

Tue, 17 Mar 2026 03:05:16 -0400

BioNxt Solutions Inc. (CSE: BNXT) announced it signed a non-binding letter of intent for potential commercialization of its sublingual cladribine oral thin film product in Eurasian Patent Organization member states.

The agreement follows recent patent grants covering BioNxt's cladribine drug delivery technology in the Eurasian region and Europe. The Eurasian Patent Organization issued Patent No. 051510 on November 14, 2025, providing protection in eight member states through June 14, 2043. The European Patent Office granted European Patent No. 4539857 on March 11, 2026, covering up to 39 European countries through the same date.

The letter of intent establishes a 60-day exclusive negotiation

BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe

Tue, 17 Mar 2026 03:05:00 -0400

VANCOUVER, BC / ACCESS Newswire / March 17, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that it has signed a non-binding letter of intent (LOI) establishing an exclusive negotiation framework for the potential commercialization of its sublingual cladribine oral thin film (ODF) product within one or more member states of the Eurasian Patent Organization (EAPO).
The LOI outlines a structured pathway toward a potential regional licensing arrangement and follows recent patent grants and decisions covering BioNxt's proprietary

BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe

Tue, 17 Mar 2026 03:05:00 -0400

VANCOUVER, BC / ACCESS Newswire / March 17, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that it has signed a non-binding letter of intent (LOI) establishing an exclusive negotiation framework for the potential commercialization of its sublingual cladribine oral thin film (ODF) product within one or more member states of the Eurasian Patent Organization (EAPO).
The LOI outlines a structured pathway toward a potential regional licensing arrangement and follows recent patent grants and decisions covering BioNxt's proprietary

BioNxt Announces Closing of Shares for Debt Settlement

Thu, 26 Feb 2026 19:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / February 26, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that, further to its news release dated January 23, 2026, the Company has issued an aggregate of 6,008,883 common shares in the capital of the Company (the "Debt Shares") at a deemed price of $0.45 per Debt Share to settle $2,704,000 in debt (the "Debt") owed to certain arm's length creditors (the "Debt Settlement"). The Debt was comprised of a principal amount of $2,600,000 and accrued interest of $104,000 pursuant

BioNxt Announces Closing of Shares for Debt Settlement

Thu, 26 Feb 2026 19:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / February 26, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that, further to its news release dated January 23, 2026, the Company has issued an aggregate of 6,008,883 common shares in the capital of the Company (the "Debt Shares") at a deemed price of $0.45 per Debt Share to settle $2,704,000 in debt (the "Debt") owed to certain arm's length creditors (the "Debt Settlement"). The Debt was comprised of a principal amount of $2,600,000 and accrued interest of $104,000 pursuant

BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis

Tue, 17 Feb 2026 03:05:00 -0400

VANCOUVER, BC / ACCESS Newswire / February 17, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that the European Patent Office (EPO) has issued a Decision to Grant European Patent No. 4539857 covering the Company's proprietary sublingual cladribine oral thin film (ODF) drug delivery technology.
The grant will take effect upon publication of the mention of grant in the European Patent Bulletin on March 11, 2026 (Bulletin 26/11). Upon assignment in designated jurisdictions, the patent will provide protection